Zhao Ning, Qin Yeshan, Liu Hongguang, Cheng Zhen
Department of Radiology, Molecular Imaging Program at Stanford (MIPS), Bio-X Program and Stanford Cancer Center, Stanford University School of Medicine, Stanford, CA, 94305, United States.
Institute of Molecular Medicine, College of Life and Health Sciences, Northeastern University, Shenyang, 110000, China.
Anticancer Agents Med Chem. 2018;18(1):74-86. doi: 10.2174/1871520617666170419143459.
The aberrant proliferation of tumor cells and abundant vasculature in tumor tissues are closely correlated with receptors that are specifically dysregulated in tumor cells. These tumor-associated targets are critical in early diagnosis and therapy selection. Ligands such as antibodies, proteins, polypeptides and polysaccharides that specifically bind to these targets can significantly improve the detection and cure rate when used as tumor imaging probes or anti-tumor agents. Compared to other targeting ligands, peptides have attracted increasingly more attention in tumor diagnostics and therapeutics because of their small sizes, high affinity, stability, ease of modification and low immunogenicity. Several peptide-based imaging probes and therapeutic agents have already been used in clinical trials. This review summarizes some of the tumor-associated targets and their corresponding peptides, as well as the potential of these peptides in cancer treatment.
肿瘤组织中肿瘤细胞的异常增殖和丰富的脉管系统与肿瘤细胞中特异性失调的受体密切相关。这些肿瘤相关靶点在早期诊断和治疗选择中至关重要。诸如抗体、蛋白质、多肽和多糖等能特异性结合这些靶点的配体，用作肿瘤成像探针或抗肿瘤药物时，可显著提高检测率和治愈率。与其他靶向配体相比，肽因其尺寸小、亲和力高、稳定性好、易于修饰且免疫原性低，在肿瘤诊断和治疗中越来越受到关注。几种基于肽的成像探针和治疗药物已用于临床试验。本文综述了一些肿瘤相关靶点及其相应的肽，以及这些肽在癌症治疗中的潜力。
